Huada, with a market value of over 100 billion, has shrunk to 20 billion and spent 11 months.

Medical Network October 19th News On October 16, Huada Gene fell in early trading, and closed at 50.50 yuan on the same day, down 10%, hitting a new low since listing, and the market value has dropped by 20 billion!

Since the beginning of the year, the stock price of Huada Gene has fallen from more than 200 yuan/share all the way, and has fallen to nearly 76%. Today, Huada's gene has dropped to 48.46 yuan, and the total market value has shrunk to the current 19.39 billion yuan (16:00 on October 17). It is shrinking by more than 80% from its peak of 100 billion market value.

As the leader of gene sequencing, after the listing of Huada Gene on July 14, 2017, its share price has been rushing all the way. On November 14, the company's stock price hit an all-time high, and reached a price of 261.99 yuan per share. Breaking through the 100 billion mark. Since then, the stock price has begun to fall.

After the release of the article "Hua Da Cancer" on July 13, Huada's share price accelerated. In mid-September 2018, the company once again encountered a 'legacy book'. As a result of this bad news, the market value of Huada Gene evaporated 2.7 billion on the same day.

From the news point of view, the recent decline in the stock price of Huada Gene, especially the early limit of October 16th, or related to the three announcements issued by Huada Gene recently.

Huada Gene announced on the evening of October 15 that the shareholder Shenzhen Qianhai Huada Gene Investment enterprise (Limited Partnership) (hereinafter referred to as 'Hua Da Investment') The plan is to reduce the holding of the company's shares by block trade or concentrated bidding to no more than 1,2003,000 shares (accounting for 3% of the company's total share capital). The shares reduced this time are July this year. On the 16th, the ban was lifted, and about 200 million shares were banned on the same day, accounting for 51.6% of the total share capital.

Huada Investment is the shareholding platform of Huada Gene Executive Team. The current directors of the company are Wang Jun, Yin Wei, Sun Yingjun, current supervisor Li Songgang, current executive Du Yutao, outgoing director Li Yingrui, outgoing executive Wang Wei and others through China. The large investment indirectly holds 66,915,154 shares of Huada Gene, accounting for 16.72% of the company's total share capital, and is the second largest shareholder of Huada Gene.

As for the reasons for the reduction of Huada Investment, the Huada Gene Announcement stated that it is the company’s own funding needs.

The above-mentioned executives have subscribed for a total of 49.925 million yuan for Huada Investment, and the corresponding capital cost per share of Huada Gene is about 0.75 yuan. According to the closing price on October 16, the reduction of the premium is 66 times. About 600 million yuan.

The most profitable was Director Wang Jun, who is an executive partner of Huada Investment, contributing 53.79%.

In addition to executives' reductions, the third-quarter earnings announcement disclosed by Huada Gene recently did not bring good news. On October 12, Huada Gene disclosed that the company's third-quarter expected profit was 1.07-122 billion yuan last year. In the same period, it was 121 million yuan, a year-on-year increase of -11.63%-0.73%; the first three quarters of earnings increased by 0.82%-5.63%. The reason is that the company has increased R&D investment in kit test and product clinical trial projects.

In addition, following the announcement of the reduction, Huada Gene announced again on the evening of October 16th, and recently received a written resignation report from Mr. Wang Jun, one of the company's directors (one of the executives). Wang Jun applied for resignation as a director of the company for personal reasons. According to Huada, Wang Jun did not hold any other positions in the Huada Gene listed company after resigning as a senior executive in 2015.

As of the disclosure date of the announcement, Wang Jun did not directly hold the company's shares, holding a 10.5% stake in Shenzhen Huada Gene Technology Co., Ltd., the controlling shareholder of the company, and holding a share of 53.7932% of the company's second largest shareholder, Huada Investment.

After the resignation, Wang Jun will not hold any position in the listed company. Wang Jun’s plan to reduce the shareholding and resign from the director is due to the need for his own funded arrangement and concentrate on developing himself. Start a business Relevant to the company. Market judges do not rule out Wang Jun's equity redemption for the development of his personal company, thus achieving a "complete delivery" with Huada Gene.

Wang Jun’s turn and leave announced the end of a dispute. At the same time, Huada’s genes are gathering strength. The information disclosed by the Shenzhen Stock Exchange shows that the company’s directors, Yin Yu, Du Yutao, Liu Na, Chen Yuqing, etc. have bought The company's stock, they have promised, based on the firm confidence in the company's future development prospects and recognition of the company's value, some directors, executives, supervisors and core key personnel plan to increase the amount of holdings not less than 40 million yuan.

On September 13, Huada Gene said in response to questions from institutional investors, in 2018, the two most important tasks for the company's management: First, let the team be more united and work together to develop; Second, we must increase R & D strength, better play the company's comprehensive advantages. 'In the early period, the company's management has increased its holdings through several times, using actual actions to demonstrate confidence in the company's future development; In the future, the company will continue to focus on the company's main business, and strive to operate and develop, I believe the market will Give the company a reasonable valuation.